Kornimate/medical-research-clean huggingface dataset:
immune response to anti covid-19 vaccine in immunocompromised patients: a cohort study

Conditions: Covid19; COVID-19 Vaccines

Summary: despite covid-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide. fortunately, sarscov2 vaccines have been developed at an unprecedented pace. while the vaccination programs are still ongoing, early reports on efficacy are mainly centered on healthy population. in chile most people have received the inactivated coronavac vaccine. data on the immune response after vaccination in immunocompromised patients is lacking. therefore, this study aims to evaluate the immune response after coronavac vaccine in 5 cohorts of immunocompromised patients and healthy controls. we will include patients with cancer, hiv, solid organ transplant and patients receiving immunomodulatory agents for rheumatic diseases.


Eligibility criteria:
general inclusion criteria: * eastern cooperative oncology group \< 3 * vaccination with 2 doses of coronavac vaccine general exclusion criteria: * previous sars-cov-2 infection * vaccination with coronavac more than 12 weeks before informed consent * intravenous immunoglobulin therapy 60 days before informed consent * any condition, that could interfere with the participant's participation during the study in the opinion of the treating investigator. cancer cohort inclusion criteria: * diagnosis of cancer in the previous 5 years (consistent biopsy is required). * life expectancy more than 12 weeks exclusion criteria: * bone marrow transplant, solid organ recipient, hiv, immunosuppressant treatment for other condition. bone marrow transplant cohort inclusion criteria: * bone marrow transplant between january 2019 and december 2020 exclusion criteria: * other cancer diagnosis during the last 5 years, solid organ recipient, hiv, immunosuppressant treatment for other condition. solid organ recipient cohort: inclusion criteria: * liver, kidney or heart transplant between january 2019 and december 2020 * active immunosuppressant treatment exclusion criteria: - cancer diagnosis during the last 5 years, bone marrow transplant, immunosuppressant treatment for other condition, hiv hiv cohort: inclusion criteria: * cd4 \<= 500 cels/mm3 documented one year before study enrollment * active antiretroviral therapy * viral load \< 200 copies/ml exclusion criteria: * cancer diagnosis during the last 5 years, bone marrow transplant or solid organ recipient, immunosuppressant treatment. rheumatic disease cohort inclusion criteria: * diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, relapsing polychondritis, behcet disease or juvenile idiopathic arthritis * chronic immunomodulatory treatment with anti-tnf, anti-il6 or anti-il17 agents exclusion criteria: * treatment with more than one biological agent. * cancer diagnosis during the last 5 years, bone marrow transplant or solid organ recipient, hiv diagnosis.
real-world insights of people with human immunodeficiency virus (hiv) infection

Conditions: HIV Infections

Summary: this study is designed to identify the burden associated with hiv and its treatment, and assess their health-related quality of life (hrqol) by measuring key hrqol domains, including satisfaction with treatment and care, and internalised stigma (isat). the study will also explore data for various important subpopulations such as subjects who are virally suppressed; who we anticipate will be the majority of study subjects. the study design is an observational, cross sectional study employing subjects' own mobile phone devices for data entry.


Eligibility criteria:
inclusion criteria: * \>= 21 years old * language:read and understand english / spanish * positive diagnosis of hiv infection by a healthcare provider (self-reported) * possesses a smartphone that has internet access exclusion criteria: * not applicable

Keywords: human immunodeficiency virus health related quality of life functional assessment of hiv infection mobile app
epidural electrical stimulation to restore hemodynamic stability and trunk control in people with spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the hemon study aims to evaluate the safety and preliminary efficacy of arc-im therapy (epidural electrical stimulation) to improve hemodynamic management and trunk control in people with sub-acute or chronic spinal cord injury (\>= 1 month post injury) between c3 and t6 inclusive, who suffer from orthostatic hypotension.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * must provide and sign the informed consent prior to any study related procedures * spinal cord injury lesion level between c3 and t6 (inclusive) * sci ≥ 1month * confirmed orthostatic hypotension * stable medical, physical and psychological condition as considered by the investigators * able to understand and interact with the study team in french or english * agrees to comply in good faith with all conditions of the study and to attend all scheduled appointments exclusion criteria: * sci related to a neurodegenerative disease * diseases and conditions that would increase the morbidity and mortality of spinal cord injury surgery * the inability to withhold antiplatelet/anticoagulation agents perioperatively * history of myocardial infarction or cerebrovascular event within the past 6 months * other conditions that would make the subject unable to participate in testing in the judgement of the investigators * clinically significant mental illness in the judgement of the investigators * botulinum toxin vesical and non-vesical injections in the previous 3 months before the enrolment * presence of significant pressure ulcers * recurrent urinary tract infection refractory to antibiotics * presence of indwelling baclofen or insulin pump * women who are pregnant (pregnancy test obligatory for woman of childbearing potential) or breast feeding, * lack of safe contraception for women of childbearing capacity, * intention to become pregnant during the course of the study, * other clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.), * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders or dementia of the participant, * participation in another study with investigational drug within the 30 days preceding and during the present study, * enrolment of the investigator, his/her family members, employees, and other dependent persons.

Keywords: spinal cord injury
post-marketing surveillance of administration of botulinum toxin type b(nerbloc)-investigation of the clinical condition and safety in patients with cervical dystonia

Conditions: Cervical Dystonia

Summary: investigation of the clinical condition and safety in patients with cervical dystonia


Eligibility criteria:
inclusion criteria: patients with cervical dystonia exclusion criteria: the patients who participated in this surveillance in the past

Keywords: torticollis rimabotulinumtoxinb
evaluation of the inhibitory effect of 5 anti-histamines in urticaria

Conditions: Urticaria

Summary: the antihistamines with inhaled steroids are the cornerstone on the symptomatic therapy in the management of patients with rhinitis and the first line of treatment in patients with urticaria. currently, the use of antihistamines has become popular due to its excellent safety profile and clinical efficacy, however to the investigators knowledge, there are no studies about the pharmacokinetic and pharmacodynamic effects of these drugs in patients of tropical latin america. the investigators main interest is to evaluate if skin test inhibition correlates with the clinical effect of five anti-histamines.

this was a randomized, double-blind, study that was conducted in six health care centers from medellín and bogotá (colombia). this study was conducted in compliance with the ethical principles of the declaration of helsinki and with good clinical practice guidelines. written informed consent was obtained from all subjects or they parents in patients under 18 years. ethical committee of university of antioquia (medellín, colombia) approved the protocol. considering the large number of articles that demonstrate the efficacy of antihistamines as first-line treatment in patients with urticaria, the ethics committee request that all participants would receive an antihistamine during the two months of the study because a placebo group would provide little information for the principal objective and the high risk of airway angioedema. thirty heath subjects were used as a control group to evaluated the characteristics of the wheal in the prick test with histamine.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of persistent allergic urticaria. * age over 12 years and at least one year with the disease * informed consent filled. * be resident of the metropolitan area of medellin. exclusion criteria: * • use of immunosuppressive drugs

Keywords: urticaria bilastine fexofenadine cetirizine ebastine desloratadine
cardiovascular effects in psoriasis patients treated with adalimumab.

Conditions: Psoriasis

Summary: severe psoriasis has been demonstrated to be associated with decreased endothelial function and an increase risk of future coronary events. although systemic therapy with immunomodulatory agents has been shown to improve psoriatic symptoms, its effects on systemic inflammation and endothelial function are unknown. in this study we want to assess the cardiovascular risks factors, endothelial dysfunction and inflammatory markers before and after treatment of moderate to severe psoriasis with an fda-approved biologic agent, adalimumab (humira).


Eligibility criteria:
inclusion criteria: * must understand and voluntarily sign an informed consent form. * must be male or female and age 18-55 years at time of consent. * must be able to adhere to the study visit schedule and other protocol requirements * have chronic plaque psoriasis for more than 6 months with a pasi score of 12 or greater at baseline. * females of childbearing potential (fcbp)‡ must have a negative urine pregnancy test at screening (visit 1). * negative ppd at screening or 3 months earlier. * have not used any biologic treatment for psoriasis in the past 12 months. exclusion criteria: * inability to provide voluntary consent * any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study * pregnant, trying to become pregnant or breastfeeding * prior diagnosis of coronary artery disease (cad) or heart disease. * systemic fungal infection * history of past or active mycobacterial infection with any species (including mycobacterium tuberculosis). latent mycobacterium tuberculosis infection as indicated by a positive (more than 15mm induration)purified protein derivative \[ppd\] skin test. subjects with a positive ppd skin test and documented completion of treatment for latent tb are eligible. subjects with a positive ppd skin test and not treated or no documentation of completion of treatment are ineligible. * history of recurrent bacterial infection (at least 3 major infections resulting in hospitalization and/or requiring intravenous antibiotic treatment within the past 2 years) * clinically significant abnormality on the chest x-ray (cxr) at screening. chest x-rays performed within 3 months prior to start of study drug are acceptable. * use of any investigational medication within 4 weeks prior to start of study drug or 5 pharmacokinetic/pharmacodynamic half-lives (whichever is longer) * history of human immunodeficiency virus (hiv) infection or hepatitis c * positive hepatitis b surface antigen at screening * malignancy or history of malignancy (except for treated \[ie, cured\] basal-cell skin carcinomas \> 3 years prior to screening) * history of any demyelinating disorder such as multiple sclerosis.

Keywords: moderate to severe chronic plaque type psoriasis
immediate effects of hamstring stretching alone or combined with myofascial release

Conditions: Hamstring Injury; Masseter; Myofascial Release; Stretching; Surface EMG; Temporomandibular Joint Disorders

Summary: to assess the immediate effects of hamstring stretching alone or combined with myofascial release of the hamstring muscle on masseter muscle activity, pressure pain threshold, active mouth opening, hamstring flexibility, and forward head flexed posture in recreationally active participants. the young, healthy, recreationally active adults aged 18-25 years were included in the study. the participants were randomly separated into two groups of equal number. static stretching alone was applied to one group and this was combined with myofascial release techniques (ssmr) for the other group. masseter muscle activity was assessed using a noraxon® surface electromyography device. both pre-and post-intervention, mechanical pressure algometer was used to measure the pressure pain threshold, hamstring flexibility was evaluated using the maximum hip flexion and active knee extension test, the maximum mouth opening (mmo) was measured with the millimetric ruler, and forward flexed posture was evaluated using the tragus to wall distance test.


Eligibility criteria:
inclusion criteria: * individuals who had no previous hamstring injury * individuals had a straight leg raise test \<80° * individuals had a pressure-pain threshold difference between two symmetrical points not exceeding 2 kg/cm2 * individuals who had no previous hamstring injury had no deviation during mouth opening and closing exclusion criteria: * acute low back pain or musculoskeletal pain in the lower extremities * recent spinal surgery * previous whiplash injury
novel controlled hypo-perfusion technique in partial nephrectomy

Conditions: Partial Nephrectomy; Renal Cell Carcinoma

Summary: many patients who are candidates for nephron-sparing surgery, partial nephrectomy is now the standard treatment with a surgical, small, clinical t1 tumor (\<7 cm). in many recent studies, partial nephrectomy provides equivalent oncologic, and superior functional, outcomes compared with the standard radical nephrectomy over the short and long term (2, 3). partial nephrectomy techniques, whether open, laparoscopic or robotic, typically involve hilar clamping, which creates the desired bloodless operative field, allowing for more precise tumor excision and renal reconstruction. this hilar clamping eventually may lead to ischemic kidney injury which can compromise the functional outcomes of the remaining kidney.we are working now to develop a novel technique of hypo-perfusion by achieving partial renal arterial clamping, with the goal of completely eliminating surgical ischemia to the renal remnant.


Eligibility criteria:
inclusion criteria: * patient must be at least 18 years old scheduled for open partial nephrectomy exclusion criteria: * no prior diagnosis of renal artery disease

Keywords: partial nephrectomy hypoperfusion renal function
outcome of extremely preterm infants who received systemic postnatal corticosteroid for bronchopulmonary dysplasia

Conditions: Bronchopulmonary Dysplasia

Summary: bronchopulmonary dysplasia is a complication of prematurity. postnatal corticosteroid is used to treat the inflammatory part of this pathology, in particular to wean premature infants from the ventilator at the end of the first month of life. however, this therapy remains controversial because it may induce suboptimal neurocognitive development. parents of infants who receive postnatal corticosteroid should be provided with information about the risks. the objective of our work was to evaluate the respiratory, neurodevelopmental and growth outcomes at 24 months corrected age of extremely preterm infants who received postnatal corticosteroid.


Eligibility criteria:
inclusion criteria: * extremely preterm infants less than 29 weeks' gestation * infants hospitalized for at least the first 30 days of life in the neonatology department of the croix-rousse hospital in lyon * infants born between january 1, 2013 and december 31, 2016 exclusion criteria: * infants with a congenital heart, lung or brain malformation * infants with a neuromuscular disease * infants with a genetic disorder * infants who died before the age of 24 months corrected age * infants lost to follow-up or with incomplete data at 24 months corrected age
determination of grass pollen allergen concentration inducing rhinoconjunctivitis symptoms in subjects allergic to grass pollen in alyatec allergen exposure chamber

Conditions: Allergic Rhinitis Due to Grass Pollen

Summary: the aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in alyatec allergen exposure chamber. four concentrations of grass pollen allergen (phl p 5) are tested during 3-hour exposures: 0, 30, 60 and 90 ng/m3.


Eligibility criteria:
main inclusion criteria: * subjects with symptoms of allergic rhinoconjunctivitis to grass pollen without associated asthma, requiring anti-allergic treatment for at least 2 consecutive pollen seasons; * subjects with positive skin prick tests to grass pollen extracts (phleum pratense): papule diameter ≥ 5 mm compared to the negative control (nacl reaction \< 2 mm)); * subjects with phl p 5 specific recombinant immunoglobulin e ≥ 0.70 kiu/l; * forced expiratory volume in 1 second (fev1) ≥ 70% of predicted value at screening and before allergenic exposures; * women of childbearing age must have a negative pregnancy test at screening and before exposure visits; main exclusion criteria: * specific immunotherapy (sit) to grass pollen allergens for more than one month in the 3 years preceding the screening visit; * ongoing specific immunotherapy to another allergen * history of anaphylaxis following exposure to grass pollen or grass sits; * asthma * ear, nose \& throat or ocular surgical intervention in the 6 months preceding inclusion;

Keywords: allergy rhinitis pollen
cryoablation of bone metastases from endocrine tumors

Conditions: Neoplasm Metastasis; Thyroid Neoplasm; Pheochromocytoma; Adrenal Neoplasm; Neuroendocrine Tumors; Bone Metastases

Summary: this study will evaluate the clinical response and safety of cone beam computed-tomography guided percutaneous cryoablation in bone metastases from thyroid, adrenal and neuroendocrine tumors in 30 patients.

thyroid neoplasms, as well as adrenal and neuroendocrine tumors have the potential to metastasize to bone. about 3% of patients with well-differentiated thyroid carcinomas develop secondary bone lesions, while adrenal and neuroendocrine tumors have 10% and 13% bone metastases rates, respectively. spinal metastases are associated to a worst prognosis. the progressive systemic disease, the post-operative complications, and the pre-operative neurologic impairment were associated to a worst global survival rate in the thyroid cancer. additionally, extensive spinal instrumentation of metastatic thyroid carcinoma was associated to greater complication rates. interventional radiology offers promising techniques for the minimally invasive approach of bone metastases. image-guided percutaneous radiofrequency ablation and cryoablation techniques have been studied in clinical trials and are considered effective options in pain palliation of patients with bone metastatic disease. these techniques may be associated with conventional treatment, as well as radiation therapy and percutaneous embolization, avoiding major surgical interventions and its complications.

Eligibility criteria:
inclusion criteria: * patients with bone metastases from thyroid, adrenal or neuroendocrine tumor diagnosis, associated to one of the following: pain; risk fracture; risk of compression of spinal cord; hypercalcemia; performance status (ecog) 0-3; mean life expectancy over one month; exclusion criteria: * age \< 18 years * active anticoagulant therapy or uncorrectable coagulopathy * pregnancy or breast feeding
impaired decision-making in adolescents

Conditions: Adolescent Psychiatry; Antisocial Personality Disorders; Substance-Related Disorders

Summary: there is clear evidence that aggressive behavior and disruptive behavior disorders (dbd) in middle childhood are associated with an increased risk for substance abuse in adolescence. however, the exact underlying mechanism of this increased risk is unknown. it is likely that a biopsychological vulnerability in some aggressive children and children with dbd makes them liable to substance use and abuse. the investigators hypothesize that deficient decision making is such a biopsychological factor. in this study the investigators aim to test the latter hypothesis by investigating the decision making ability in a group of adolescents with dbd with and without substance use disorders. decision-making is assessed with the iowa gambling task (gt). this task mimics real-life situations in the way it factors uncertainty, reward and punishment. the gt is specifically designed to assess impaired decision-making in individuals who are unable to learn from their mistakes and make decisions that repeatedly lead to negative consequences. this characteristic may be common to individuals with externalizing disorders such as dbd, psychopathy, and substance use disorders.

this study consists of two substudies with adolescents in the age of 14-21 years. the first study group consist of adolescents with dbd with (n=30) and without (n=30) substance use disorders. these adolescents are recruited from orthopsychiatric, forensic psychiatric, and judicial institutions. the second study group consists of a) ex-patients of the utrecht coping power program (ucpp)who previously participated to a follow-up study, and b) ex-patients who were treated as a child at an outpatient clinic of the umc utrecht. these latter groups were taken together and subdivided into a group with (n=30) and without (n=30) substance use problems. for both studies healthy controls (n=80) are recruited. the investigators will start with healthy controls from earlier studies, and those are extented and will serve as control group for both studies.

Eligibility criteria:
inclusion criteria: * having a disc diagnosis dbd exclusion criteria: * having the disc diagnosis schizophrenia

Keywords: disruptive behavior disorders, substance abuse, iowa gambling task, decision making.